Need for Bioequivalence Standards that Reflect the Clinical Importance of the Complex Pharmacokinetics of Paliperidone Palmitate Long-Acting Injectable Suspension

• Auteurs principaux: Ric M Procyshyn (Auteur), Joel W Lamoure (Auteur), Martin A Katzman (Auteur), Pamela L Skinner (Auteur), Stephen E Sherman (Auteur)
• Format: Livre
• Publié: Frontiers Media S.A., 2020-01-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Paliperidone palmitate is a second generation antipsychotic, approved for the treatment of schizophrenia in the form of the long-acting injectable (LAI) products INVEGA SUSTENNA® (once monthly injection) and INVEGA TRINZA® (once every 3 months injection). Paliperidone palmitate dissolves slowly afte...